DNAY - Codex DNA top and bottom lines misses lead to 24% decline

Codex DNA's (DNAY -23.3%) Q4 2021 results that missed on both the top and bottom lines have led to a major decline in share price. The company's net loss widened by ~124% to ~$12.5M compared to the prior-year period. Codex DNA was hurt in the quarter by a more than doubling of total operating expenses to ~$13M from ~$6.1M in Q4 2020. Revenue of ~$3.1M in the quarter was a ~58.8% year-over-year increase. The company ended the year with $82.8M in cash. For 2022, the company guiding total revenue between $19M and $21M.

For further details see:

Codex DNA top and bottom lines misses lead to 24% decline